Objectives: Peripheral arterial disease (PAD) is estimated to affect 15% to 30% of the female U.S. population by 80 years of age. Women with PAD have different incidences of traditional modifiable risk factors as compared with men and are suspected to be underdiagnosed owing to atypical presentation, poor screening and an underappreciation of the prevalence of PAD in women. Additionally, women have faster functional decline as part of the natural course of their disease. For these reasons, we used the national Vascular Quality Initiative (VQI) database of femoropopliteal bypasses to identify non-mortality-related outcomes with female gender bias and to track gender attributable risk over time.
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Methods: Patients who underwent femoral-popliteal bypass, without prior open revascularization or amputation, and with occlusive pathology (n ¼ 7139) were selected for analysis. Seventy of 184 variables showed gender bias. Ambulatory status (AS), treatment indication (IND) and discharge location (DL) were selected for logistic regression. The cohort was further divided into four-time periods and risk associated with year of surgery among females was determined.
Results: Females were more likely to have decreased ambulatory ability (HR, 1.48; P < .001), be treated for critical limb ischemia (CLI; HR, 1.60; P < .001) and be discharged to a nursing or rehabilitation facility (HR, 1.61; P < .001) at time of first bypass (Table) . Over the four time periods assessed, the risk attributable to female gender for impaired AS, CLI as indication and skilled nursing facility as DL remained constant (HR, 1.27-1.58, 1.48-1.67 and 1.56-2.07, respectively; Fig) . When year of surgery was used as a covariate for regression analysis, the year of intervention was not significantly associated with IND or DL. However, surgery year was significantly associated with decreased AS (HR, 1.039; P ¼ .028; Table) .
Conclusions: Female gender remains associated with decreased ambulatory function and more advanced femoropopliteal disease at time of first bypass. Among females, the year of surgery was not significantly associated with IND or DL but did confer increased risk for difficulty ambulating. This suggests that associations between female gender, AS, IND, and DL have at best has remained constant. This study demonstrates that women with PAD continue to be treated at more advanced stages of disease compared with men and that continued progress in this area is necessary. Objectives: Pharmacologic treatment of peripheral arterial disease (PAD) comprises of antiplatelet therapy (APT), blood pressure control, and cholesterol optimization. Guidelines provide class I recommendations on APT prescription; nevertheless, there is a lack of data on the actual treatment of patients with PAD. Our study provides insight into the use of APT among patients in primary and secondary care with newly diagnosed PAD in The Netherlands, based on real-world information.
Methods: We conducted a retrospective cohort study among patients newly diagnosed with PAD from 2010 to 2014 with at least 1-year database follow-up. Newly diagnosed was defined as no previous PAD diagnosis record in the database and no prescription of P2Y12 inhibitors or aspirin in the preceding year. Data were obtained from the PHARMO Database Network, a population-based network of electronic healthcare records (primary and secondary healthcare settings) in The Netherlands. The source population for this study comprised 951,886 individuals.
Results: Between 2010 and 2014, 3.683 newly diagnosed patients with PAD were identified. Most patients (about 90%) were diagnosed in primary care. The majority of patients were in primary care at the end of the study (83%). Nearly two-fifths of all patients (39.3%) were dispensed aspirin as mono-APT (with or without statin therapy). To 2.4% of all patients, P2Y12 inhibitors (with or without statins) were dispensed as mono-APT. Dual-APT (DAPT) in the form of aspirin in combination with a P2Y12 inhibitor was dispensed to 8.2% of the study population. Revascularization within the available follow-up was recorded for 105 individuals (3%). The majority of patients with a recorded revascularization had no recorded P2Y12 inhibitor dispensing (62%). Almost all P2Y12 inhibitor dispensing after revascularization (38%) were as DAPT with aspirin (85%), with (83%) or without (3%) a statin. One-half of the patients (50.1%) had no recorded APT dispensing. Within this group, 49% received statins.
Conclusions: In this study, we found that more than one-half of all patients with newly diagnosed PAD do not get treatment to the standard of (international) guideline recommendations on APT. Evaluation and improvement of platelet aggregation inhibitor prescription and thereby improved (secondary) CVE prevention is urgently warranted.
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